Drugmakers kicked off 2019 with price increases in the United States on more than 250 prescription drugs, including the world’s top-selling medicine Humira, although the pace of price hikes was slower than during 2018.
South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.
Insurance Commissioner Dave Jones filed a complaint on behalf of the State of California against AbbVie Inc., alleging the drugmaker gave illegal kickbacks to healthcare providers to prescribe the company’s blockbuster medicine Humira.
There is a new player in the southern California biotech industry as new venture firm Westlake Village BioPartners launched with a $320 million fund.
Britain’s Indivior was subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.
Starbucks Corp. and other roasters and retailers must serve up a cancer warning with coffee sold in California, a Los Angeles judge ruled.
California’s top court opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies.
The trade group representing U.S. drugmakers filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices.
A California jury ruled in favor of Johnson & Johnson in a lawsuit by a woman who said she developed the cancer mesothelioma after being exposed to asbestos in the company’s talc-based products including J&J’s Baby Powder.